Critical Analysis of Parkinson’s Disease Models and Cell-Based Therapy

Chapter
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 10)

Abstract

The degeneration of neurons because of genetic mutations and other factors in aging populations causes serious complications in normal brain function, which can result in a variety of progressive dysfunctions. Parkinson’s disease (PD) is one type of these dysfunctions that constitutes approximately 0.3% of the total population and 1% of the total old-age population (over 60years). Because of the severity of this disease, it has drawn attention from medical and scientific communities around the world. The existing treatments, such as L-DOPA administration and/or deep brain surgery (DBS), have been found to further complicate the case of the patient. Therefore, alternate therapies have been investigated. Currently, cell-based therapy is a potential alternative to the previously mentioned treatments because of the promising results obtained from animal experiments and limited clinical trials. The experimental Parkinson’s disease models have significantly increased our knowledge on the progression of this disease and the scope of cell therapy. At the same time, the data from these models also raise some questions concerning the relevance of these models in a clinical setting and the efficacy of the treatment.

Keywords

Embryonic Stem Cell Dopaminergic Neuron Mitochondrial Protein Complex Fetal Ventral Mesencephalic Tissue Deep Brain Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Alberio T, Lopiano L, Fasano M (2012) Cellular models to investigate biochemical pathways in Parkinson’s disease. FEBS J 279:1146–1155PubMedCrossRefGoogle Scholar
  2. Altman J, Das GD (1965) Post-natal origin of microneurones in the rat brain. Nature 207:953–956PubMedCrossRefGoogle Scholar
  3. Anglade P, Vyas S, Hirsch EC, Agid Y (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12:603–610PubMedGoogle Scholar
  4. Bayer SA, Wills KV, Triarhou LC, Ghett B (1995) Time of neuron origin and gradients of neurogenesis in midbrain dopaminergic neurons in the mouse. Exp Brain Res 105:191–199PubMedGoogle Scholar
  5. Blandini F, Armentero MT (2012) Animal models of Parkinson’s disease. FEBS J 279:1156–1166PubMedCrossRefGoogle Scholar
  6. Chan CS, Guzman J, Ilijic E, Mercer J, Rick C, Tkatch T, Meredith GE, Surmeier DJ (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 447:1081–1086PubMedCrossRefGoogle Scholar
  7. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245PubMedCrossRefGoogle Scholar
  8. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, Jackson-Lewis V, Javitch JA, Ballatori N, Przedborski S, Tieu K (2009) The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106:8043–8048PubMedCrossRefGoogle Scholar
  9. Doshi K (2011) Long-term surgical and hardware-related complications of deep brain stimulation. Stereotact Funct Neurosurg 89:89–95PubMedCrossRefGoogle Scholar
  10. Fahn S (1996) The case of the frozen addicts: how the solution of an extraordinary medical mystery spawned a revolution in the understanding and treatment of Parkinson’s disease. N Engl J Med 335:2002–2003CrossRefGoogle Scholar
  11. Fenelon G, Mahieux F, Huon R, Ziegler M (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733–745PubMedCrossRefGoogle Scholar
  12. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW (2000) Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson’s disease. Mov Disord 15:485–489PubMedCrossRefGoogle Scholar
  13. Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D (2006) Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 395:124–128PubMedCrossRefGoogle Scholar
  14. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460:1132–1135PubMedCrossRefGoogle Scholar
  15. Jackson-Lewis V, Blesa J, Przedborski S (2012) Animal models of Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S183–S185PubMedCrossRefGoogle Scholar
  16. Jin GZ, Cho SJ, Choi EG, Lee YS, Yu XF, Choi KS, Yee ST, Jeon JT, Kim MO, Kong IK (2008) Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro. Cell Biol Int 32:1433–1438PubMedCrossRefGoogle Scholar
  17. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature 418:50–56PubMedCrossRefGoogle Scholar
  18. Kim J, Su SC, Wang H, Cheng AW, Cassady JP, Lodato MA, Lengner CJ, Chung CY, Dawlaty MM, Tsai LH, Jaenisch R (2011) Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 9:413–419PubMedCrossRefGoogle Scholar
  19. Koller WC, Rueda MG (1998) Mechanism of action of dopaminergic agents in Parkinson’s disease. Neurology 50:S11–S14PubMedCrossRefGoogle Scholar
  20. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med 14:504–506PubMedCrossRefGoogle Scholar
  21. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, Studer L (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551PubMedGoogle Scholar
  22. Lindvall O, Barker RA, Brustle O, Isacson O, Svendsen CN (2012) Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10:151–155PubMedCrossRefGoogle Scholar
  23. Lu XH, Fleming SM, Meurers B, Ackerson LC, Mortazavi F, Lo V, Hernandez D, Sulzer D, Jackson GR, Maidment NT, Chesselet MF, Tang MW (2009) Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci 29:1962–1976PubMedCrossRefGoogle Scholar
  24. Ma Y, Tang C, Chaly T, Greene P, Breeze R, Fahn S, Freed C, Dhawan V, Eidelberg D (2010) Dopamine cell implantation in Parkinson’s disease: long-term clinical and 18F-DOPA PET outcomes. J Nucl Med 51:7–15PubMedCrossRefGoogle Scholar
  25. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW (2003) Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 179:38–46PubMedCrossRefGoogle Scholar
  26. Muthane UB, Swamy HS, Satishchandra P, Subhash MN, Rao S, Subbakrishna D (1994) Early onset Parkinson’s disease: are juvenile- and young-onset different? Mov Disord 9:539–544PubMedCrossRefGoogle Scholar
  27. Pang ZP, Yang N, Vierbuchen T, Ostermeier A, Fuentes DR, Yang TQ, Citri A, Sebastiano V, Marro S, Sudhof TC, Wernig M (2011) Induction of human neuronal cells by defined transcription factors. Nature 476:220–223PubMedGoogle Scholar
  28. Rhee YH, Ko JY, Chang MY, Yi SH, Kim D, Kim CH, Shim JW, Jo AY, Kim BY, Lee L, Lee SH, Suh W, Park CH, Koh HC, Lee YS, Lanza R, Kim KS (2011) Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest 121:2326–2335PubMedCrossRefGoogle Scholar
  29. Samii A, Nutt JG, Ransom BR (2004) Parkinson’s disease. Lancet 363:1783–1793PubMedCrossRefGoogle Scholar
  30. Schwarz SC, Wittlinger J, Schober R, Storch A, Schwarz J (2006) Transplantation of human neural precursor cells in the 6-OHDA lesioned rats: effect of immunosuppression with cyclosporine A. Parkinsonism Relat Disord 12:302–308PubMedCrossRefGoogle Scholar
  31. Singer TP, Ramsay RR (1990) Mechanism of the neurotoxicity of MPTP: an update. FEBS Lett 274:1–8PubMedCrossRefGoogle Scholar
  32. Swistowski A, Peng J, Liu Q, Mali P, Rao MS, Cheng L, Zeng X (2012) Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 28:1893–1904CrossRefGoogle Scholar
  33. Talpade DJ, Greene JG, Higgins DS Jr, Greenamyre JT (2000) In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [3H]-dihydrorotenone. J Neurochem 75:2611–2621PubMedCrossRefGoogle Scholar
  34. Trzaska KA, Kuzhikandathil EV, Rameshwar P (2007) Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 25:2797–2808PubMedCrossRefGoogle Scholar
  35. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107–110PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Stem Cell Biology LaboratoryNational Institute of ImmunologyNew DelhiIndia

Personalised recommendations